Literature DB >> 9105845

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.

F Tessier1, C Quentin.   

Abstract

The in vitro activity of fosfomycin in combination with ceftazidime, imipenem, amikacin, or ciprofloxacin was studied by an agar plate checkerboard method against 40 clinical isolates of Pseudomonas aeruginosa with various antibiotic resistance profiles. Fosfomycin/ciprofloxacin appeared to be the most effective combination (synergy 15%, addition 80%, indifference 5%), followed by fosfomycin/amikacin (synergy 7.5%, addition 52.5%, indifference 40%), fosfomycin/imipenem (addition 37%, indifference 63%), and fosfomycin/ceftazidime (addition 20%, indifference 80%). The effects of the combinations were not significantly influenced by the antibiotic susceptibility patterns of the strains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105845     DOI: 10.1007/bf01709477

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

Review 1.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 2.  Plasmid-encoded fosfomycin resistance.

Authors:  J E Suárez; M C Mendoza
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm.

Authors:  H Kumon; N Ono; M Iida; J C Nickel
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

4.  Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro.

Authors:  H S Heineman; W M Lofton
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

5.  Beta-lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in Pseudomonas aeruginosa.

Authors:  J A Reguera; F Baquero; J Berenguer; M Martinez-Ferrer; J L Martinez
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

6.  Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.

Authors:  V M Figueredo; H C Neu
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

7.  Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli.

Authors:  N X Chin; N M Neu; H C Neu
Journal:  Drugs Exp Clin Res       Date:  1986

8.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

  8 in total
  10 in total

1.  Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis.

Authors:  Selma Tobudic; Peter Matzneller; Brigitte Stoiser; Judith Maria Wenisch; Markus Zeitlinger; Andreas Vychytil; Walter Jaeger; Michaela Boehmdorfer; Gottfried Reznicek; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

2.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates.

Authors:  G Samonis; S Maraki; D E Karageorgopoulos; E K Vouloumanou; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-31       Impact factor: 3.267

4.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

5.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

6.  Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

Authors:  M E Falagas; M D Kanellopoulou; D E Karageorgopoulos; G Dimopoulos; P I Rafailidis; N D Skarmoutsou; E A Papafrangas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

7.  The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa.

Authors:  Alfredo Castañeda-García; Alexandro Rodríguez-Rojas; Javier R Guelfo; Jesús Blázquez
Journal:  J Bacteriol       Date:  2009-09-04       Impact factor: 3.490

Review 8.  Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Authors:  Anneke Corinne Dijkmans; Natalia Veneranda Ortiz Zacarías; Jacobus Burggraaf; Johan Willem Mouton; Erik Bert Wilms; Cees van Nieuwkoop; Daniel Johannes Touw; Jasper Stevens; Ingrid Maria Catharina Kamerling
Journal:  Antibiotics (Basel)       Date:  2017-10-31

9.  In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae.

Authors:  Wei Yu; Qixia Luo; Qingyi Shi; Chen Huang; Xiao Yu; Tianshui Niu; Kai Zhou; Jiajie Zhang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2018-04-24       Impact factor: 4.003

10.  Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.

Authors:  David L MacLeod; Lynn M Barker; Jennifer L Sutherland; Suzanne C Moss; Jesse L Gurgel; Thomas F Kenney; Jane L Burns; William R Baker
Journal:  J Antimicrob Chemother       Date:  2009-08-13       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.